Human IFN-γ Antibody - Fontolizumab Biosimilar

Anti-human IFN gamma - Fontolizumab biosimilar - CAS #326859-36-3

Binding of Anti-hIFN-γ Fontolizumab

Anti-hIFN-γ-hIgG1 is a biosimilar antibody of Fontolizumab, a therapeutic antibody that targets interferon gamma (IFN-γ). This monoclonal antibody (mAb) blocks the interaction of IFN-γ with its receptor. Fontolizumab has been clinically tested as an immunosuppressive drug to treat inflammatory diseases, including Crohn's disease and psoriasis.

 More details

Anti-hIFN-γ-hIgG1 comprises the variable region of Fontolizumab and the IgG1 constant region of Fontolizumab with high effector functions. 

This antibody can be used with HEK-Blue™ IFN-γ cells for screening and neutralization assays to block recombinant human IFN-γ-induced signaling (see figure).

Key features

• Each lot is functionally tested and validated.
• The complete sequence of the antibody construct was verified.
• The absence of endotoxins is determined using the EndotoxDetect™ assay.

All InvivoGen products are for internal research use only, and not for human or veterinary use.

Figures

Dose-dependent inhibition of HEK-Blue™ IFN-γ cells response using Fontolizumab biosimilar. Increasing concentrations of Anti-hIFN-γ-hIgG1 (0.1 ng/ml - 10 µg/ml) were incubated with recombinant human (h)IFN-γ (3 ng/ml) for 1 h before the addition of HEK-Blue™ IFN-γ cells. After overnight incubation, SEAP activity in the cell culture supernatant was assessed using QUANTI-Blue™ Solution. Data are shown in percentage of activity (%) (mean ± SEM).

Specifications

Application: Neutralization assay, ELISA

Isotype:  Human IgG1, kappa

Recommended isotype control: Human IgG1

Target: Human IFN-γ

Species reactivity: Human

Clone: Fontolizumab, HuZAF™

Cas number: 326859-36-3

Sterility: 0.2 µm filtration

Source: CHO cells 

Production: Animal-free

Purification: Protein A

Molecular weight: 148 kDa

Physical form: Lyophilized

Formulation buffer: Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative: Azide-free

Reconstitution buffer: Sterile water (not provided)

Purity: ≥ 95 %

Quality control: Each lot is functionally tested and validated.

Contents

Anti-hIFNγ-hIgG1 purified monoclonal antibody is provided azide-free and lyophilized. It is available in two quantities:

• hifng-mab1: 100 µg
• hifng-mab1-03: 3 x 100 µg

 The product is shipped at room temperature.

Upon receipt, store lyophilized antibody at -20°C.

 Lyophilized product is stable for at least 1 year.

 Avoid repeated freeze-thaw cycles.

Details

Fontolizumab background

Fontolizumab (aka HuZAF™) is a therapeutic, humanized monoclonal antibody (mAb) that targets the human interferon-gamma (IFN-γ) cytokine [1, 2]. By binding to IFN-γ, Fontolizumab prevents it from interacting with its receptor (IFN-γR) on the surface of immune cells, thus inhibiting downstream inflammatory response. Fontolizumab was used as an immunosuppressive drug to treat inflammatory diseases, including Crohn's disease and psoriasis. While the mode of action was promising, clinical trials did not demonstrate sufficient clinical benefit [3, 4].

References:

1. Hommes D.W., et al., 2006. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut, 55(8):1131-1137.
2. Reinisch W et al., 2006. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut, 55(8):1138-1144.
3. Reinisch W et al., 2009. Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Infl Bowel Dis., 16(2):233-242.
4. Harden J.L., et al., 2015. Humanized anti-IFNg (HuZAF) in the treatment of psoriasis. J. Aller Clin Immunol. 135(2):553.